# Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor

> **NCT04840862** · PHASE4 · COMPLETED · sponsor: **University of Southern California** · enrollment: 6 (actual)

## Conditions studied

- Drug Drug Interaction

## Interventions

- **DRUG:** Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]
- **DRUG:** Rifabutin 300mg

## Key facts

- **NCT ID:** NCT04840862
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-09
- **Primary completion:** 2024-05-30
- **Final completion:** 2024-05-30
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04840862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04840862, "Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04840862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*